Markets Stocks Economy Crypto Earnings Banking Energy
Home Markets Feature
Markets · Exclusive

Dealmakers Reshape Pharma, Robotics, and Delivery with Multi-Billion Takeovers

Dealmakers Reshape Pharma, Robotics, and Delivery with Multi-Billion Takeovers
Markets · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Jul 16, 2026 3 min read

Dealmakers are on a roll, with a flurry of takeovers sweeping across rare-disease drugs, industrial robotics, and food delivery. The latest moves include Angelini Pharma's $4.1 billion purchase of Catalyst, Uber's $14.8 billion bid for Delivery Hero, and other significant acquisitions that signal a busy period for mergers and acquisitions (M&A) in diverse sectors.

What's Driving the Deal Spree?

Companies are increasingly turning to acquisitions to expand their reach, gain new technologies, or consolidate market share. In the pharmaceutical space, Angelini Pharma's $4.1 billion Catalyst buyout targets rare-disease drugs, a high-growth niche where specialized treatments command premium prices. Meanwhile, in industrial robotics, ABB's $5.5 billion cash deal for Rotork marks its largest acquisition ever, aiming to strengthen its automation and flow control capabilities. And in food delivery, Uber's $14.8 billion cash bid for Delivery Hero would create a global delivery giant, though antitrust hurdles loom large.

Key Deals at a Glance

  • Angelini Pharma / Catalyst: A $4.1 billion acquisition focused on rare-disease treatments, backed by state and Blackstone support.
  • Uber / Delivery Hero: A $14.8 billion cash bid to combine Uber Eats with Delivery Hero's global platform, with closing expected by 2027.
  • ABB / Rotork: A $5.5 billion all-cash deal to acquire the industrial flow control specialist, winning board backing.

What It Means for Investors

For everyday investors, this wave of M&A signals confidence among corporate leaders that they can generate growth through acquisitions rather than relying solely on organic expansion. However, big deals come with risks. Integration challenges, regulatory scrutiny, and debt loads can weigh on acquirers' stock prices. For example, Uber's bid for Delivery Hero faces antitrust reviews in multiple jurisdictions, which could delay or derail the deal. Similarly, Angelini's Catalyst buyout may face regulatory hurdles in the pharmaceutical sector.

Investors should also consider the broader market backdrop. The Federal Reserve's recent Beige Book showed steady growth and easing price pressures, which can encourage dealmaking by making financing more predictable. Yet, rising interest rates in the past have made borrowing more expensive, so cash-rich companies like Uber and ABB have an advantage in using cash rather than debt for acquisitions.

What to Watch Next

Key developments to monitor include regulatory decisions on Uber's Delivery Hero bid, which could set a precedent for tech and delivery mergers. Also, watch for integration updates from ABB and Angelini, as successful integration is critical for realizing deal value. For investors holding shares in any of these companies, earnings reports will reveal how these acquisitions impact financials.

In summary, the current dealmaking frenzy reflects a dynamic corporate landscape where companies are betting big on strategic acquisitions. While the potential for growth is significant, so are the risks. As always, diversification and a long-term perspective remain key for navigating such market moves.

More from this story

Next article · Don't miss

Galp's Moeve Downstream Merger Delayed to H2, Berenberg Holds Rating

Berenberg lifted its 2026 earnings forecast for Galp Energia but maintained a hold rating as the planned downstream merger with Spain's Moeve is delayed to H2. The unchanged €20 price target implies a lower valuation multiple, reflecting increased deal timing

Read the story →
Galp's Moeve Downstream Merger Delayed to H2, Berenberg Holds Rating